However, the Inflation Reduction Act and subsequent CMS guidance opened a narrow door: plans may cover semaglutide when its prescribed for cardiovascular risk reduction in patients who already have established cardiovascular disease
Combination therapies are being designed to target multiple pathways (e.g., curb hunger and speed up metabolism) to improve both weight loss and tolerability
GHK-Cus 50mg dose in KLOW directly addresses this by stimulating collagen synthesis up to 70% above baseline and elastin production by 30%
Indeed, phase 3 trials are evaluating retatrutide in populations with T2D, OSA, knee OA, CKD and cardiovascular disease who may particularly benefit
Note: Medication is only prescribed when clinically appropriate
For this reason, many patients will continue to take the medication for a bit longer even after they have reached their goal weight, and will definitely benefit from meeting with a nutritionist and personal trainer throughout their weight loss treatment and for however long they need the support afterwards to help them sustain the results long-term
